Barrett MT et al. Clinical study of genomic drivers in pancreatic ductal adenocarcinoma. Br J Cancer 2017;117(4):572-82. Abstract
Binder KR et al. A phase II, single arm study of maintenance rucaparib in patients with platinum-sensitive advanced pancreatic cancer and a pathogenic germline or somatic mutation in BRCA1, BRCA2 or PALB2. Proc AACR 2019;Abstract CT234.
Chiorean EG et al. Performance status dynamics during treatment with nab-paclitaxel plus gemcitabine versus gemcitabine alone for metastatic pancreatic cancer. Cancer Manag Res 2018;10:1389-96. Abstract
Chiorean EG et al. Real-world comparative effectiveness of nab-paclitaxel plus gemcitabine (nab-P/G) vs FOLFIRINOX (FFX) in patients (pts) with advanced pancreatic cancer (aPC). Proc ESMO 2018;Abstract 724P.
Conroy T et al; Canadian Cancer Trials Group and the Unicancer GI-PRODIGE Group. FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer. N Engl J Med 2018;379(25):2395-406. Abstract
Golan T et al. Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer. N Engl J Med 2019;381(4):317-32. Abstract
Lawrence RY et al. Single-shot celiac plexus radiosurgery in pancreatic cancer: Palliative and functional outcomes — Final results of a prospective clinical trial. Proc ASCO 2019;Abstract 309.
Le D et al. Mismatch-repair deficiency predicts response of solid tumors to PD-1 blockade. Science 2017;357(6349):409–13. Abstract
Neoptolemos JP et al; European Study Group for Pancreatic Cancer. Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): A multicentre, open-label, randomised, phase 3 trial. Lancet 2017;389(10073):1011-24. Abstract
O’Reilly EM et al. Phase 1 trial evaluating cisplatin, gemcitabine, and veliparib in 2 patient cohorts: Germline BRCA mutation carriers and wild-type BRCA pancreatic ductal adenocarcinoma. Cancer 2018;124(7):1374-82. Abstract
Ouyang G et al. Gemcitabine plus cisplatin versus gemcitabine alone in the treatment of pancreatic cancer: A meta-analysis. World J Surg Oncol 2016;14:59. Abstract
Pishvaian MJ et al. Final report of a phase I/II study of veliparib (Vel) in combination with 5-FU and oxaliplatin (FOLFOX) in patients (pts) with metastatic pancreatic cancer (mPDAC). Proc ASCO 2019;Abstract 4015.
Pishvaian MJ et al. Molecular profiling of patients with pancreatic cancer: Initial results from the Know Your Tumor initiative. Clin Cancer Res 2018;24(20);5018–27. Abstract
Seeber A et al. Association of BRCA-mutant pancreatic cancer with high tumor mutational burden (TMB) and higher PD-L1 expression. Proc ASCO 2019;Abstract 4133.
Shroff R et al. Rucaparib monotherapy in patients with pancreatic cancer and a known deleterious BRCA mutation. JCO Precis Oncol 2018;2018. Abstract
Singhi AD et al. Real-time targeted genome profile analysis of pancreatic ductal adenocarcinomas identifies genetic alterations that might be targeted with existing drugs or used as biomarkers. Gastroenterology 2019;156(8):2242-53. Abstract
Sohal DP et al. Metastatic pancreatic cancer: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 2016;34(23):2784-96. Abstract
Sonbol MB et al. Second-line treatment in patients with pancreatic ductal adenocarcinoma: A meta-analysis. Cancer 2017;123(23):4680-6. Abstract
Tempero M et al. APACT: Phase III, multicenter, international, open-label, randomized trial of adjuvant nab-paclitaxel plus gemcitabine (nab-P/G) vs gemcitabine (G) for surgically resected pancreatic adenocarcinoma. Proc ASCO 2019;Abstract 4000.
Uhl W et al. NEONAX trial: Neoadjuvant plus adjuvant or only adjuvant nab-paclitaxel plus gemcitabine for resectable pancreatic cancer, a phase II study of the AIO pancreatic cancer group (AIO-PAK-0313) — Safety interim analysis. Proc ASCO 2019;Abstract 4128.
Wang-Gillam A et al. NAPOLI-1 phase III study of liposoma irinotecan in metastatic pancreatic cancer: Final overall survival analysis and characteristics of long-term survivors. Eur J Cancer 2019;108:78-87. Abstract
Zhen DB et al. Biomarker-driven and molecularly targeted therapies for pancreatic adenocarcinoma. Semin Oncol 2018;45(3):107-15. Abstract